Evidence map›Paper›PMID 35618966›Full record

ArticleBulletin of experimental biology and medicine2022

Experimental Study of Antitumor Activity of Pefagtal Addressed to αvβ3 Integrins.

N A Popova, V P Nikolin, V I Kaledin, I A Serova, E A Matyunina, M A Bakarev, E L Lushnikova, A N Vologodskii

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

N A PopovaFederal Research Center Institute of Cytology and Genetics, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.
V P NikolinFederal Research Center Institute of Cytology and Genetics, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.
V I KaledinFederal Research Center Institute of Cytology and Genetics, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.
I A SerovaFederal Research Center Institute of Cytology and Genetics, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.
E A MatyuninaBiotechnology Company, Moscow, Russia.
M A BakarevFederal Research Center of Fundamental and Translational Medicine, Novosibirsk, Russia.
E L LushnikovaFederal Research Center of Fundamental and Translational Medicine, Novosibirsk, Russia. pathol@inbox.ru.
A N VologodskiiBiotechnology Company, Moscow, Russia.
Institute of Cytology and Genetics · RUAll-Russian Scientific Research Institute of Food Biotechnology · RUFederal Research Center of Fundamental and Translational Medicine · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We studied the effect of a new targeted drug Pefagtal that represents a conjugate in which the MS2 phage filled with a substance toxic to cells (thallium salts) is covalently linked to peptides containing the RGD motif. The antitumor and pronounced antimetastatic effects of Pefagtal were demonstrated on transplanted mouse tumors differing in histological type and status of metastasis: Krebs-2 ascites adenocarcinoma of the mammary gland, Lewis lung adenocarcinoma, hepatoma-29, and lung adenocarcinoma. It is assumed that the RGD motif mediates primary binding of the construct to αvβ3 and αvβ5 integrins that are predominantly overexpressed in the endothelial cells of tumor blood vessels and in tumor and metastatic cells.

Indexed as

Adenocarcinoma of LungCarcinoma, HepatocellularLiver NeoplasmsAnimalsEndothelial CellsIntegrin alphaVbeta3MiceOligopeptidesIntegrin alphaVbeta3Oligopeptidesdrug Pefagtalmetastasesmice tumorstargeted therapyαvβ3 integrins

Identifiers

PMID35618966
OpenAlexW4281742214

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.